CoChat

Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer

Open access
Singhal, Sharad S., Sehrawat, Archana, Sahu, Mukesh, Singhal, Preeti, Vatsyayan, Rit, Rao Lelsani, Poorna Chandra, Yadav, Sushma, Awasthi, Sanjay · 2010 · International Journal of Cancer
Cited by 57

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

RLIP76 is a stress‐responsive membrane protein implicated in the regulation of multiple cellular signaling pathways. It represents the predominant glutathione‐conjugate (GS‐E) transporter in cells. We have shown that RLIP76 plays a crucial role in defending cancer cells from radiation and chemotherapeutic toxin‐mediated apoptosis, and that its inhibition by antibodies or depletion by siRNA or antisense causes apoptosis in a number of cancer cell types. We demonstrated for the first time that the striking anti‐neoplastic effects with no evident toxicity in terms of either weight loss or metabolic effects are also demonstrable for the antibody, antisense and siRNA in a renal cell xenografts model of Caki‐2 cells (Singhal et al., Cancer Res., 2009, 69: 4244). Present studies were performed to determine if RLIP76 targeting is more broadly applicable in other kidney cancer cell lines, to compare the signaling effects of RLIP76 antisense with kinase inhibitors used in treatment of renal cell carcinoma, and to determine whether kinase inhibitors were substrates for transport by RLIP76. Results of these studies show that sorafenib as well as sunitinib are substrates for transport by RLIP76 thus are competitive inhibitors of GS‐E transport. Furthermore, kinase inhibition in the ERK as well as PI3K pathways by RLIP76 depletion is more profound and consistent and is more widely apparent in a number of renal carcinoma cell lines. These studies offer strong support for our overall hypothesis that RLIP76 is an overarching anti‐apoptosis mechanism that, if inhibited, can be more broadly effective in the treatment of renal cell carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.24767

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 57

Metadata

Authors
Singhal, S. S., Sehrawat, A., Sahu, M., Singhal, P., Vatsyayan, R., Rao Lelsani, P. C., Yadav, S., & Awasthi, S.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2009-12-22
Volume
126
Issue
6
Pages
1327-1338
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2051997184
Cited by
57
References
5
FWCI
2.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. https://app.cochat.ai/papers/10.1002/ijc.24767
The paper
Singhal, S. S., Sehrawat, A., Sahu, M., Singhal, P., Vatsyayan, R., Rao Lelsani, P. C., Yadav, S., & Awasthi, S. (2010). Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.24767

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.